How do medical affairs teams use AI for content strategy?

Anthony Stackman ·

Medical affairs teams are using AI primarily to accelerate content development, improve scientific accuracy at scale, and tailor materials for different stakeholder audiences. The technology works best on time-intensive tasks — literature synthesis, slide deck drafting, audience segmentation — freeing medical writers and strategists to focus on scientific rigour and strategic judgement. The questions below unpack how that works in practice, from the tools teams are using to the compliance risks they need to manage.

What types of content do medical affairs teams actually produce?

Medical affairs teams produce a broad range of scientific and educational materials for healthcare professionals, payers, internal stakeholders, and patients. Core outputs include medical education programmes, MSL field tools, congress materials, publications, payer value dossiers, and disease awareness content. Each serves a distinct purpose and must meet different regulatory and scientific standards.

The scope is wider than many outside the function appreciate. On the scientific side, teams develop data packages, clinical summaries, and evidence gap analyses. On the stakeholder engagement side, they produce materials for advisory boards, expert meetings, and key opinion leader interactions. For internal audiences, that means training resources, pipeline briefings, and cross-functional alignment documents.

Patient-facing content is an increasingly significant part of the mix, requiring plain-language adaptation of complex clinical data without sacrificing accuracy. Market access teams rely on medical affairs to build the health economic and outcomes research narratives that support reimbursement submissions. The result is a content function that spans highly technical regulatory documentation through to accessible public health communications.

How is AI being used to support scientific content development?

The primary driver is volume. Large language models can synthesise literature, draft structured summaries, and generate first-pass content from clinical data — significantly reducing the time medical writers spend on early-stage document production. The human role shifts toward review, scientific validation, and strategic framing.

In practice, the most common applications are automated literature surveillance, where AI tools monitor and summarise new publications relevant to a therapeutic area, and structured content generation, where AI drafts slide decks, briefing documents, or MSL field materials from approved data sources. Some teams are also using AI to convert long-form clinical study reports into audience-specific summaries, a task that previously required considerable manual effort.

AI also supports gap analysis, helping teams identify where their evidence base is thin relative to competitor data or payer expectations. Applied early in a product lifecycle, that kind of strategic intelligence can directly inform publication planning and medical education priorities. The technology does not replace scientific judgement — but it can make that judgement faster and better informed.

What are the compliance risks of using AI in medical communications?

The main risks are inaccurate content generation, unverified citations, and outputs that fall outside the boundaries set by industry codes such as the ABPI Code of Practice in the UK or equivalent frameworks in the US and EU. AI models can produce plausible-sounding but factually incorrect scientific statements, which makes human expert review non-negotiable for any regulated content.

Provenance is a second significant concern. AI-generated content can draw on training data that is outdated, incorrectly attributed, or not aligned with the approved label for a specific product. In medical affairs, where every claim must be substantiated by a specific, accessible reference, that creates a real governance challenge. Teams need clear processes for verifying that AI-assisted outputs are traceable back to approved source materials.

There are also emerging questions around data privacy, particularly when proprietary clinical data or commercially sensitive information is entered into third-party AI platforms. Most enterprise AI tools now offer private deployment options, but medical affairs teams should work with legal and compliance functions to establish clear policies before integrating any AI tool into their content workflows. The regulatory environment around AI-generated promotional and non-promotional material is still developing, so governance frameworks need to be built with the flexibility to adapt.

Which AI tools are medical affairs teams currently using?

In 2026, medical affairs teams are using a combination of general-purpose large language models and specialist life sciences platforms. General tools such as GPT-4 and Claude are widely used for drafting and summarisation, while specialist platforms built for life sciences — including Veeva Vault PromoMats integrations, Inizio Engage’s AI tools, and emerging medcomms-specific platforms — offer more structured compliance guardrails and audit trail functionality.

Literature management platforms with AI layers, including Elsevier’s ScienceDirect AI features and Semantic Scholar integrations, are increasingly used by medical information and publications teams to navigate the volume of published data in a therapeutic area more efficiently than traditional manual search methods.

For content production specifically, some agencies and in-house teams are building proprietary AI-assisted workflows that combine a large language model with a curated, approved data library, keeping outputs within the boundaries of validated scientific content. This hybrid approach — AI generates structure and draft language; trained medical writers apply scientific and regulatory oversight — is currently the most defensible model for regulated content environments.

How does AI help medical affairs teams personalise content for different audiences?

The practical gain is speed of adaptation. A single clinical dataset can be transformed into a payer value story, an HCP education module, a patient-facing summary, and an MSL field tool, with AI handling the structural and linguistic adaptation while medical affairs professionals ensure each version meets the appropriate scientific and regulatory standard.

Audience segmentation is another area where AI adds genuine value. By analysing engagement data, specialty characteristics, and content interaction patterns, AI tools can help teams understand which messages resonate with which audiences and refine their content strategy accordingly — moving personalisation from an intuitive exercise to a data-informed one.

For external expert engagement, AI can help teams tailor pre-meeting briefing documents, advisory board materials, and congress content to reflect the specific therapeutic interests and publication history of individual key opinion leaders. The creative and scientific quality of that personalisation still depends on the people shaping the strategy, but AI removes much of the manual effort that previously made true personalisation impractical at scale.

Should medical affairs teams build AI capabilities in-house or work with specialist agencies?

Most teams will benefit from a hybrid model: developing internal AI literacy and governance capability while partnering with specialist agencies for content production that requires both scientific depth and creative execution. Building everything in-house demands significant investment in technology, training, and compliance infrastructure that many teams — particularly in smaller pharma companies or biotech startups — cannot sustain independently.

The case for in-house AI development is strongest where a team has high content volume, a stable therapeutic area focus, and the internal medical writing resource to validate AI outputs rigorously. In those environments, proprietary AI workflows can deliver real efficiency gains and protect commercially sensitive data. Even so, well-resourced in-house teams often find that the creative quality and strategic perspective required for high-impact medical communications benefit from external partnership.

Specialist agencies that combine scientific expertise with AI-assisted production workflows offer a practical middle path — deploying AI tools at scale while applying the medical writing, regulatory, and creative oversight that regulated content demands. The most useful question is not build versus buy, but where AI adds the most value in your specific content workflow, and whether the internal capability exists to govern it safely.

How Wizzard helps medical affairs teams with AI content strategy

We are a specialist medical communications agency working with pharmaceutical companies, biotech startups, and healthcare organisations to produce scientific content that is both rigorous and genuinely engaging. For medical affairs teams navigating AI integration, we offer:

  • Medical writing and editorial oversight that ensures AI-assisted outputs meet scientific and regulatory standards
  • Audience-specific content adaptation across HCP, payer, patient, and internal stakeholder channels
  • Strategic planning support for medical education, MSL tools, congresses, and expert engagement programmes
  • Creative execution informed by consumer advertising expertise, producing communications that are bigger, brighter, and braver than clients expect
  • Integrated production across film, digital, and print formats, managed within relevant industry codes and governance frameworks

If you are looking to build a smarter, more scalable content strategy, get in touch with Wizzard to talk through how we can help.

Related Articles